Back to Report Store Home

Global Cancer Supportive Care Therapeutics Market to 2022 – Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets

  • Published: Mar-2017
  • Report Code: GBIHC434MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 10

2.1 Therapy Area Introduction 10

2.2 Epidemiology 10

2.2.1 Cancer Pain 10

2.2.2 Chemotherapy Side Effects 11

2.2.3 Oral Mucositis 11

2.3 Pathophysiology 11

2.3.1 Bone Metastasis 11

2.3.2 Oral mucositis 12

2.3.3 Cancer Pain 12

2.3.4 Chemotherapy-Induced Nausea and Vomiting 12

2.3.5 Chemotherapy-Induced Anemia 13

2.3.6 Chemotherapy-Induced Neutropenia 13

2.4 Etiology 13

2.5 Symptoms 14

2.6 Diagnosis and Grading 14

2.7 Treatment 17

2.7.1 Chemotherapy-Induced Nausea and Vomiting 17

2.7.2 Chemotherapy-Induced Neutropenia 18

2.7.3 Chemotherapy-Induced Anemia 18

2.7.4 Cancer Pain 19

2.7.5 Bone Metastases 19

2.7.6 Oral Mucositis 19

3 Key Marketed Products 21

3.1 Overview 21

3.2 Neulasta (pegfilgrastim) – Amgen 22

3.3 Xgeva (denosumab) – Amgen 23

3.4 Aranesp/Nesp (darbepoetin alfa) – Amgen/Kyowa Hakko Kirin 24

3.5 Xofigo (radium Ra 223 dichloride) – Bayer 26

3.6 Nucynta (tapentadol hydrochloride) – Depomed 27

3.7 Epogen/Procrit (epoetin alfa) – Amgen/Johnson & Johnson 29

3.8 Neupogen (Filgrastim) – Amgen 30

3.9 Aloxi (palonosetron hydrochloride) – Eisai, Helsinn and Otsuka 32

3.10 Conclusion 33

4 Pipeline Landscape Assessment 35

4.1 Overview 35

4.2 Pipeline Development Landscape 35

4.3 Molecular Targets in the Pipeline 38

4.4 Clinical Trials 40

4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 41

4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 45

4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 49

4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 53

4.4.5 Conclusion 57

4.5 Assessment of Key Pipeline Products 57

4.5.1 Tanezumab – Pfizer and Eli Lilly 57

4.5.2 Rolontis (Eflapegrastim) – Spectrum Pharmaceuticals 59

4.5.3 Conclusion 61

5 Multi-scenario Market Forecast to 2022 62

5.1 Overall Market Size 62

5.2 Generic Penetration 64

5.3 Revenue Forecast by Molecular Target 67

5.3.1 Cytokine Receptors 67

5.3.2 G Protein-Coupled Receptors 68

6 Company Analysis and Positioning 70

6.1 Revenue and Market Share Analysis by Company 72

6.2 Amgen – Can it Retain its Market-Leading Position Despite Patent Expiries for Key Products? 76

6.3 Bayer – Will Revenue from Xofigo Continue to Increase during the Forecast Period? 77

6.4 Heron Therapeutics – Will New Approvals Allow a Small Company to Obtain a Significant Market Share? 78

6.5 Insys Therapeutics – Can Reformulations Be Commercially Successful if Generics are Available? 79

6.6 Kyowa Hakko Kirin – How will the Japanese Cancer Supportive Care Market React to Patent Expiries for Some of the Therapy Area’s Most Successful Drugs? 80

6.7 Daiichi Sankyo – Will Revenue from Injectafer and Ranmark Continue to Increase during the Forecast Period? 81

6.8 Company Landscape 82

6.8.1 Marketed and Pipeline Portfolio Analysis 83

7 Strategic Consolidations 85

7.1 Licensing Deals 85

7.1.1 Deals by Region, Year and Value 85

7.1.2 Deals by Indication, Stage of Development and Value 86

7.1.3 Deals by Molecule Type, Molecular Target and Value 88

7.1.4 Table for Licensing Deals with a Disclosed Value 90

7.2 Co-development Deals 93

7.2.1 Deals by Region, Year and Value 93

7.2.2 Deals by Indication, Stage of Development and Value 94

7.2.3 Deals by Molecule Type, Mechanism of Action and Value 96

7.2.4 Table for Co-development Deals with a Disclosed Value. 98

8 Appendix 99

8.1 Bibliography 99

8.2 All Pipeline Drugs by Phase of Development 103

8.2.1 Discovery 103

8.2.2 Preclinical 105

8.2.3 IND/CTA-filed 114

8.2.4 Phase I 114

8.2.5 Phase II 116

8.2.6 Phase III 119

8.2.7 Pre-registration 121

8.2.8 Unknown 122

8.3 Abbreviations 123

8.4 Disease List 124

8.5 Methodology 124

8.5.1 Coverage 124

8.5.2 Secondary Research 125

8.5.3 Market Size and Revenue Forecasts 125

8.5.4 Pipeline Analysis 125

8.5.5 Competitive Landscape 126

8.6 Contact Us 126

8.7 Disclaimer 126

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5817
Or click here to contact us
Secure Payments
Cards